Evidence map›Paper›PMID 23922715›Full record

ArticlePloS one2013

Development of a nuclear morphometric signature for prostate cancer risk in negative biopsies.

Peter H Gann, Ryan Deaton, Anup Amatya, Mahesh Mohnani, Erika Enk Rueter, Yirong Yang, Viju Ananthanarayanan

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Peter H GannDepartment of Pathology, University of Illinois at Chicago, Chicago, Illinois, United States of America. pgann@uic.edu
Ryan Deaton
Anup Amatya
Mahesh Mohnani
Erika Enk Rueter
Yirong Yang
Viju Ananthanarayanan
University of Illinois Chicago · USNew Mexico State University · USUniversity of Chicago · USUniversity of New Mexico · US

Funding

Validation of Digital Morphometry for Cancer Risk in Benign Prostate BiopsiesR01CA155301 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GANN, PETER H. · 2011 to 2015
$1.7M
Effects of Lycopene on High-Risk Prostatic TissueR01CA090759 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GANN, PETER H. · 2002 to 2005
$1.4M
NCI NIH HHS R01 CA090759NCI NIH HHS R01 CA155301NCI NIH HHS R01 CA90759
6 · The paper itself

Abstract

backgroundOur objective was to develop and validate a multi-feature nuclear score based on image analysis of direct DNA staining, and to test its association with field effects and subsequent detection of prostate cancer (PCa) in benign biopsies.

methodsTissue sections from 39 prostatectomies were Feulgen-stained and digitally scanned (400×), providing maps of DNA content per pixel. PCa and benign epithelial nuclei were randomly selected for measurement of 52 basic morphometric features. Logistic regression models discriminating benign from PCa nuclei, and benign from malignant nuclear populations, were built and cross-validated by AUC analysis. Nuclear populations were randomly collected <1 mm or >5 mm from cancer foci, and from cancer-free prostates, HGPIN, and PCa Gleason grade 3-5. Nuclei also were collected from negative biopsy subjects who had a subsequent diagnosis of PCa and age-matched cancer-free controls (20 pairs).

resultsA multi-feature nuclear score discriminated cancer from benign cell populations with AUCs of 0.91 and 0.79, respectively, in training and validation sets of patients. In prostatectomy samples, both nuclear- and population-level models revealed cancer-like features in benign nuclei adjacent to PCa, compared to nuclei that were more distant or from PCa-free glands. In negative biopsies, a validated model with 5 variance features yielded significantly higher scores in cases than controls (P = 0.026).

conclusionsA multifeature nuclear morphometric score, obtained by automated digital analysis, was validated for discrimination of benign from cancer nuclei. This score demonstrated field effects in benign epithelial nuclei at varying distance from PCa lesions, and was associated with subsequent PCa detection in negative biopsies. IMPACT: This nuclear score shows promise as a risk predictor among men with negative biopsies and as an intermediate biomarker in Phase II chemoprevention trials. The results also suggest that subvisual disturbances in nuclear structure precede the development of pre-neoplastic lesions.

Indexed as

Area Under CurveBiopsyCase-Control StudiesCell NucleusFalse Negative ReactionsHumansMaleProstatic NeoplasmsRisk FactorsStaining and Labeling

Identifiers

PMID23922715
PMCPMC3724855
OpenAlexW1978342884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.